The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism.
CYP3A
CYP450 metabolism
Eplerenone
Metabolic phenotype
Personalized medicine
Pharmacogenetics
Journal
Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027
Informations de publication
Date de publication:
15 Oct 2019
15 Oct 2019
Historique:
received:
02
05
2019
revised:
30
07
2019
accepted:
05
08
2019
pubmed:
14
8
2019
medline:
24
9
2019
entrez:
14
8
2019
Statut:
ppublish
Résumé
Cytochrome P450 mediated metabolism is the rate-limiting step of elimination for many drugs. CYP3A4 is the most abundant hepatic isoform and CYP3A4/5 metabolize the largest fraction of drugs. Pharmacogenetic studies have not been able to characterize population variability in CYP3A4 activity because few variant alleles associated with aberrant enzyme activity have been found. Substrate probes such as midazolam and testosterone have been utilized in-vivo and in-vitro to determine catalytic activity of these enzymes, but they suffer from several limitations. Eplerenone, an aldosterone antagonist, is also metabolized by CYP3A enzymes, and it has the potential to be an excellent substrate probe for CYP3A4/5. Eplerenone's primary metabolite, 6 beta-hydroxyeplerenone is formed preferentially via CYP3A4, however, the relative contribution of CYP3A5 to the 21-hydroxyeplerenone metabolite formation is unknown. Through in-vitro microsomal incubations with recombinant CYP3A4 and CYP3A5 enzymes, we identified their relative contributions to 21-hydroxyeplerenone metabolism. The 21-hydroxy metabolite is formed preferentially via CYP3A5 V
Identifiants
pubmed: 31408697
pii: S0378-4274(19)30218-8
doi: 10.1016/j.toxlet.2019.08.003
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Eplerenone
6995V82D0B
Cytochrome P-450 Enzyme System
9035-51-2
Cytochrome P-450 CYP3A
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-13Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.